Ramona L Doyle, MD
Pulmonary Disease · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Office
- 1
Offices
1 location · University of California San Francisco · 1,780 clinicians in this group
Hospitals listed: UCSF Medical Center · Zuckerberg San Francisco General Hosp & Trauma Ctr. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Doyle’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence G68150 · Current
Licensed to practise in California · since 1990 · expires 2028-01-31 · Emory University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
- Zuckerberg San Francisco General Hosp & Trauma CtrSan Francisco, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of San Francisco Health Network, which runs 2 hospitalsPatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.449, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.37, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.538, Oct 2024 – Sep 2025
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Zuckerberg San Francisco General Hosp & Trauma Ctr
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 7 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.449 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.37 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.538 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.9 (0 to 1.91) · 667 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.12 (0.76 to 1.49) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 195.34 (147.34 to 243.34) · 76 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 114 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.2 · 48 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.5 · 201 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.5 · 214 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.3 · 261 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 1,351 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.07 to 0.5) · 4,709 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.39 (0.19 to 0.59) · 4,644 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.34 (2.11 to 6.56) · 795 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.59 (0 to 3.28) · 234 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.85 (1.33 to 4.38) · 861 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.95 (0.25 to 17.64) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6 (2.01 to 9.98) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.17 to 3.14) · 167 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.79 (0.08 to 1.49) · 4,129 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 35 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.709 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.769 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 41 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 227 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 28.6 · 257 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 75.1 · 239 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.2 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 175 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.3 (8.3 to 15.1) · 175 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 37 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 132 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.6 (10.4 to 17.9) · 966 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.8 to 1.7) · 88 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,644 patients answered, 16% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$3,417
Medicare paid this office $3,417 for 24 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 22 | $2,401 | $75 |
Who their Medicare patients are
24 Original Medicare patients in 2024. Average age 71 · Health risk score 2.35. Above the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · COPD 58% · Heart failure 50%.
The office billed $25,093, Medicare allowed $4,696 and paid $3,417; for 43 services of 5 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 24 | 43 | 71 | 2.35 | $25,093 | $3,417 |
| 2023 | 23 | 47 | 71 | 2.53 | $28,970 | $4,292 |
| 2022 | 30 | 48 | 69 | 2.12 | $23,368 | $3,938 |
| 2021 | 27 | 41 | 67 | 2.39 | $21,587 | $3,218 |
| 2020 | 23 | 42 | 65 | 2.70 | $24,779 | $3,136 |
| 2019 | 17 | 27 | 63 | 2.04 | $20,595 | $2,363 |
| 2018 | 26 | 46 | 64 | 2.15 | $33,159 | $4,225 |
| 2017 | 24 | 38 | 64 | 2.29 | $24,378 | $3,280 |
| 2016 | 28 | 55 | 64 | 2.39 | $34,227 | $4,593 |
| 2015 | 27 | 51 | 62 | 2.03 | $33,506 | $4,675 |
| 2014 | 23 | 34 | 65 | 1.90 | $23,234 | $3,280 |
| 2013 | 32 | 52 | 62 | 1.74 | $32,681 | $4,684 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Return visit (30+ min) | 19 | $3,070 | $85 |
2022: 1 service
| Return visit (30+ min) | 17 | $1,834 | $87 |
2021: 1 service
| Return visit (30+ min) | 17 | $1,506 | $68 |
2020: 1 service
| Return visit (30+ min) | 18 | $2,223 | $72 |
2019: 1 service
| Long return visit (40+ min) | 16 | $1,999 | $87 |
2018: 1 service
| Long return visit (40+ min) | 19 | $2,931 | $92 |
2017: 2 services
| Long return visit (40+ min) | 18 | $2,286 | $95 |
| Return visit (30+ min) | 11 | $844 | $65 |
2016: 2 services
| Long return visit (40+ min) | 12 | $2,151 | $98 |
| Return visit (30+ min) | 21 | $1,727 | $64 |
2015: 2 services
| Long return visit (40+ min) | 19 | $2,868 | $96 |
| Return visit (30+ min) | 12 | $1,048 | $70 |
2014: 1 service
| Long return visit (40+ min) | 18 | $2,478 | $95 |
2013: 1 service
| Long return visit (40+ min) | 16 | $2,496 | $92 |
Drugs they prescribed that Part D paid
$1,124,733
Pharmacies billed $1,124,733 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
59 generic and 67 brand-name prescriptions · $1,124,733 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Uptravi | 17 | $434,806 | $25,577 |
| Opsumit | 29 | $353,412 | $12,187 |
| Ambrisentan | 13 | $99,622 | $7,663 |
Year by year
| 2024 | 126 | 23 | None | 53% | $1,124,733 |
| 2023 | 113 | 24 | 0% (0) | 58% | $1,024,990 |
| 2022 | 113 | 15 | 0% (0) | 50% | $1,170,541 |
| 2021 | 111 | 12 | 0% (0) | 55% | $1,055,600 |
| 2020 | 172 | 20 | 0% (0) | 47% | $1,357,206 |
| 2019 | 341 | 28 | 0% (0) | 42% | $2,056,284 |
| 2018 | 483 | 30 | None | 55% | $2,696,990 |
| 2017 | 195 | 20 | None | 73% | $1,560,728 |
| 2016 | 165 | 19 | 0% (0) | 78% | $951,055 |
| 2015 | 278 | 22 | 0% (0) | 67% | $960,558 |
| 2014 | 282 | 21 | None | 56% | $678,480 |
| 2013 | 308 | 29 | None | 43% | $457,292 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Tyvaso Dpi | 16 | $357,801 | $22,363 |
| Uptravi | 14 | $342,990 | $24,499 |
| Opsumit | 18 | $222,727 | $12,374 |
| Ambrisentan | 12 | $41,619 | $3,468 |
2022: 3 drugs
| Orenitram Er | 26 | $567,138 | $21,813 |
| Uptravi | 19 | $411,363 | $21,651 |
| Ambrisentan | 17 | $59,830 | $3,519 |
2021: 3 drugs
| Orenitram Er | 24 | $457,470 | $19,061 |
| Uptravi | 21 | $398,440 | $18,973 |
| Ambrisentan | 23 | $63,138 | $2,745 |
2020: 6 drugs
| Orenitram Er | 24 | $475,747 | $19,823 |
| Uptravi | 21 | $431,584 | $20,552 |
| Letairis | 17 | $175,104 | $10,300 |
| Ambrisentan | 29 | $99,132 | $3,418 |
| Tadalafil | 22 | $43,308 | $1,969 |
| Alyq | 15 | $12,533 | $836 |
2019: 10 drugs
| Letairis | 59 | $627,772 | $10,640 |
| Uptravi | 27 | $541,034 | $20,038 |
| Orenitram Er | 26 | $491,317 | $18,897 |
| Tadalafil | 52 | $130,650 | $2,513 |
| Adcirca | 17 | $67,683 | $3,981 |
| Alyq | 15 | $34,252 | $2,283 |
| Torsemide | 21 | $898 | $43 |
| Spironolactone | 30 | $399 | $13 |
| Digoxin | 17 | $246 | $14 |
| Escitalopram | 12 | $54 | $4 |
2018: 13 drugs
| Letairis | 105 | $1,006,036 | $9,581 |
| Uptravi | 48 | $794,683 | $16,556 |
| Orenitram Er | 24 | $432,339 | $18,014 |
| Adcirca | 63 | $234,439 | $3,721 |
| Opsumit | 12 | $110,748 | $9,229 |
| Tadalafil | 29 | $110,325 | $3,804 |
| Sildenafil | 20 | $2,973 | $149 |
| Digoxin | 32 | $873 | $27 |
| Torsemide | 17 | $680 | $40 |
| Spironolactone | 32 | $632 | $20 |
| Furosemide | 15 | $89 | $6 |
| Amlodipine Besylate | 12 | $60 | $5 |
| Omeprazole | 12 | $36 | $3 |
2017: 4 drugs
| Uptravi | 29 | $508,239 | $17,525 |
| Letairis | 51 | $472,039 | $9,256 |
| Orenitram Er | 24 | $401,298 | $16,721 |
| Adcirca | 13 | $47,096 | $3,623 |
2016: 5 drugs
| Orenitram Er | 16 | $274,763 | $17,173 |
| Tracleer | 25 | $238,910 | $9,556 |
| Letairis | 26 | $222,472 | $8,557 |
| Adcirca | 46 | $143,271 | $3,115 |
| Sildenafil | 11 | $544 | $49 |
2015: 7 drugs
| Letairis | 40 | $301,361 | $7,534 |
| Tracleer | 31 | $265,043 | $8,550 |
| Adcirca | 63 | $168,183 | $2,670 |
| Sildenafil | 19 | $12,114 | $638 |
| Spironolactone | 19 | $500 | $26 |
| Amlodipine Besylate | 17 | $123 | $7 |
| Furosemide | 18 | $50 | $3 |
2014: 8 drugs
| Tracleer | 40 | $305,591 | $7,640 |
| Letairis | 22 | $157,191 | $7,145 |
| Adcirca | 62 | $128,118 | $2,066 |
| Sildenafil | 22 | $18,291 | $831 |
| Potassium Chloride | 18 | $1,125 | $62 |
| Spironolactone | 21 | $855 | $41 |
| Furosemide | 29 | $377 | $13 |
| Omeprazole | 19 | $231 | $12 |
2013: 10 drugs
| Tracleer | 25 | $171,427 | $6,857 |
| Letairis | 20 | $131,336 | $6,567 |
| Revatio | 11 | $68,147 | $6,195 |
| Adcirca | 29 | $50,159 | $1,730 |
| Sildenafil | 37 | $28,858 | $780 |
| Spironolactone | 39 | $975 | $25 |
| Potassium Chloride | 12 | $768 | $64 |
| Furosemide | 38 | $174 | $5 |
| Omeprazole | 14 | $145 | $10 |
| Digox | 13 | $85 | $7 |
Money from drug and device companies
$181 in 2025
| 2025 | 2 | 7 | None | $181 |
| 2024 | 3 | 4 | $10,250 | $10,456 |
| 2021 | 1 | 1 | $3,824 | $3,824 |
| 2020 | 1 | 2 | $11,303 | $11,303 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Merck Sharp & Dohme | Winrevair | $155 | 6 payments
|
| Actelion Pharmaceuticals US | Opsynvi | $26 | 1 payment
|
See all 7 published payments
| Merck Sharp & Dohme | Meals · 2025-11-19 | Winrevair | $24 |
| Actelion Pharmaceuticals US | Meals · 2025-10-29 | Opsynvi | $26 |
| Merck Sharp & Dohme | Meals · 2025-10-01 | Winrevair | $17 |
| Merck Sharp & Dohme | Meals · 2025-08-06 | Winrevair | $31 |
| Merck Sharp & Dohme | Meals · 2025-07-09 | Winrevair | $28 |
| Merck Sharp & Dohme | Meals · 2025-04-30 | Winrevair | $27 |
| Merck Sharp & Dohme | Meals · 2025-01-29 | Winrevair | $27 |
See earlier years (2024, 2021, 2020)
2024: $10,456
| Alexion Pharmaceuticals | None | $10,250 | 1 payment
|
| Merck Sharp & Dohme | Winrevair | $156 | 2 payments
|
| Actelion Pharmaceuticals US | None | $50 | 1 payment
|
2021: $3,824
| GlaxoSmithKline | None | $3,824 | 1 payment
|
2020: $11,303
| GlaxoSmithKline | None | $11,303 | 2 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 74.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1497863567
- Licence
- CA G68150California G68150: Current · expires 2028-01-31
- Trained
- Emory University School of Medicine, 1988
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X)
- Mailing address
- 2680 Hanover St, Palo Alto, CA, 94304
- NPI first listed
- 2006-08-28
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.